AA76-lipid
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
200Oi10 is an ionizable lipidoid evaluated in a comparative mouse study of pancreatic mRNA delivery. Its reported activity depends on administration route and helper-lipid composition. The paper subsequently focuses on 306Oi10; those later macrophage-transfer, beta-cell and tolerability results are not evidence for 200Oi10.
Open full Formulation & Performance →
200Oi10-specific results from Figures 1B and 2B, with the complete SI checked to prevent attribution of 306Oi10 results.
The 200Oi10 structure in SI Figure S1 was checked against the catalog connectivity. The catalog molecular weight and formula are retained; paper results are not batch release specifications.
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| 200Oi10 | DC60545 | 1277.01 | 35 | 0.446953 |
| DOPE | Not uniquely mapped | 744.03 | 16 | 0.119045 |
| Cholesterol | DCD-041 | 386.65 | 46.5 | 0.179792 |
| C14-PEG2000 (source label) | Not uniquely mapped | Not established | 2.5 | Not calculable from disclosed data |
This table is the IV/IP comparison composition. The separate helper-lipid comparison uses 35:40:22.5:2.5, with DOPE, PS or DOTAP. The source gives a 10:1 lipidoid:mRNA mass ratio. PEG-lipid exact identity/MW is not resolved from the source label, so DMG-PEG2000 is not substituted.
Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.
| Component | MW | Molar ratio | Mass (mg) | Mass % |
|---|---|---|---|---|
| 200Oi10 | ||||
| DOPE | ||||
| Cholesterol | ||||
| C14-PEG2000 (source label) |
| Experiment | Lipid:helper:cholesterol:PEG molar ratio | Helper lipid | Source |
|---|---|---|---|
| Route comparison | 35:16:46.5:2.5 | DOPE | Main Fig. 1B and Methods. |
| Helper-lipid comparison | 35:40:22.5:2.5 | DOPE, PS or DOTAP in separate groups | Main Fig. 2B and Methods. |
| N/P reporting | Methods state 7.8 for DOPE/PS and 8.8 for 40% DOTAP LNPs | These are reported method-level values, not recalculated product specifications. | No 200Oi10-specific N/P calculation is inferred from 10:1 w/w. |
| Comparison | Finding | Study context |
|---|---|---|
| Intraperitoneal vs intravenous | IP delivery increased pancreatic reporter expression relative to IV in the compared formulations. | Female C57BL/6 mice, luciferase mRNA 0.5 mg/kg; 3 h; n=3/group; main Fig. 1B. |
| DOPE vs PS vs DOTAP | Pancreatic signal was broadly similar across helpers, while DOTAP reduced off-target liver/spleen expression. | Same RNA dose and 3 h endpoint; main Fig. 2B. |
| Overall expression | 200Oi10 generated the lowest overall luminescent signal among the lipidoids in the helper comparison. | Main results text. A greater pancreatic fraction is not necessarily a greater absolute pancreatic signal. |
| Exact pancreatic percentage | Not assigned. | Previously cited secondary figure-derived percentages are not treated as exact primary-source measurements. |
| Topic | Evidence boundary |
|---|---|
| Macrophage-mediated transfer and beta-cell expression | Later experiments followed 306Oi10 with DOTAP; not assigned to 200Oi10. |
| Disease-model efficacy and tolerability | Later efficacy/safety outcomes belong to the selected follow-up formulation, not automatically all screened lipidoids. |
| Particle size, PDI, encapsulation and pKa | No target-specific numerical record established for 200Oi10 in the reviewed main/SI. |
| Original figures | Figures 1 and 2 contain all three lipid groups. For this product, read panel B; other panels are comparators. |


| CAS No. | Not available |
| Chemical Name | 200Oi10 |
| Synonyms | 200,Oi,10, 200Oi,10 |
| SMILES | CC(C)CCCCCCCOC(=O)CCN(CCC(=O)OCCCCCCCC(C)C)CCN(CCC(=O)OCCCCCCCC(C)C)CCN1CCN(CCN(CCC(=O)OCCCCCCCC(C)C)CCC(=O)OCCCCCCCC(C)C)CC1 |
| Formula | C75H145O10N5 |
| M.Wt | 1,277.01 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication |
|
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 7.8308 mL | 1.5662 mL | 783.08 μL |
| 25 mg | 19.5770 mL | 3.9154 mL | 1.9577 mL |
| 50 mg | 39.1540 mL | 7.8308 mL | 3.9154 mL |
| 100 mg | 78.3079 mL | 15.6616 mL | 7.8308 mL |
| 250 mg | 195.7698 mL | 39.1540 mL | 19.5770 mL |
Contact our team with the catalog number and requested quantity.